SymbolANRO
NameALTO NEUROSCIENCE, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, California, 94041, United States
Telephone+1 650 200-0412
Fax
Email
Websitehttps://www.altoneuroscience.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001999480
Description

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.

Additional info from NASDAQ:
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.

2026-08-14 18:19

New Form SCHEDULE 13G/A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352632 <b>Size:</b> 11 KB

Read more
2026-08-14 17:12

New Form SCHEDULE 13G/A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000902664-26-003498 <b>Size:</b> 10 KB

Read more
2026-08-14 09:31

New Form SCHEDULE 13G/A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005199 <b>Size:</b> 11 KB

Read more
2026-08-12 20:14

(30% Negative) ALTO NEUROSCIENCE, INC. (ANRO) Reports Q3 2026 Financial Results

Read more
2026-08-12 20:03

Alto Neuroscience, Inc. - Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Read more
2026-08-12 20:03

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Read more
2026-07-20 18:11

New Form SCHEDULE 13G - Alto Neuroscience, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0000935836-26-000361 <b>Size:</b> 15 KB

Read more
2026-07-13 11:47

Alto Neuroscience, Inc. - Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Read more
2026-06-15 12:03

Alto Neuroscience, Inc. - Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Read more
2026-06-15 12:03

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Read more
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Apollo Armband DEVICE Approved Fatigue COMPLETED NCT04983342
Apollo Wearable DEVICE Approved Stress Disorders, Post-Traumatic RECRUITING NCT05274230
Total products: 2